The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
Open Access
- 30 October 2014
- journal article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
Abstract
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.Keywords
This publication has 26 references indexed in Scilit:
- Trends in Canadian Respiratory Clinical Trials from 2001 to 2011Canadian Respiratory Journal, 2014
- Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adultsJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescentsJournal of Allergy and Clinical Immunology, 2011
- Geographical variations in the prevalence of atopic sensitization in six study sites across CanadaAllergy, 2010
- Recommendations for appropriate sublingual immunotherapy clinical trialsJournal of Allergy and Clinical Immunology, 2009
- Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitisAllergy, 2006
- Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.2006
- Long-Term Clinical Efficacy of Grass-Pollen ImmunotherapyNew England Journal of Medicine, 1999
- IgG4 blocking effect on the release of antigen-specific histamine.1993
- CROSS-ALLERGENICITY AMONG THE GRASSES1985